ProfileGDS5678 / 1429304_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 39% 42% 41% 44% 42% 38% 39% 48% 42% 57% 46% 42% 37% 41% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9428739
GSM967853U87-EV human glioblastoma xenograft - Control 22.9590942
GSM967854U87-EV human glioblastoma xenograft - Control 32.9546841
GSM967855U87-EV human glioblastoma xenograft - Control 42.9576244
GSM967856U87-EV human glioblastoma xenograft - Control 52.9133842
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9536738
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9508839
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1294848
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9360742
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.451557
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0739846
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9284542
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8410637
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9496741